[ad_1]
Summers Worth Companions, an funding administration firm, launched its third-quarter 2025 investor letter. A replica of the letter could be downloaded right here. The Summers Worth Fund LP returned a web return of 20.4% web in Q3 2025, surpassing the 12.4% return of the Russell 2000 Index ETF (IWM) and the 12.5% return for the Russell 2000 Worth Index ETF (IWN). Yr-to-date, the fund is up 4.9% web in comparison with 10.3% and eight.9% returns for the indexes, respectively. As well as, you’ll be able to verify the fund’s high 5 holdings to search out out its greatest picks for 2025.
In its third-quarter 2025 investor letter, Summers Worth Companions highlighted shares akin to Ligand Prescription drugs Included (NASDAQ:LGND). Ligand Prescription drugs Included (NASDAQ:LGND) is a biopharmaceutical firm that operates biopharmaceutical belongings. The one-month return of Ligand Prescription drugs Included (NASDAQ:LGND) was 11.58%, and its shares gained 85.60% of their worth over the past 52 weeks. On November 18, 2025, Ligand Prescription drugs Included (NASDAQ:LGND) inventory closed at $207.05 per share, with a market capitalization of $4.075 billion.
Summers Worth Companions said the next concerning Ligand Prescription drugs Included (NASDAQ:LGND) in its third quarter 2025 investor letter:
“Ligand Prescription drugs Included (NASDAQ:LGND) operates a novel enterprise mannequin inside the pharmaceutical trade as a royalty aggregator, requiring little or no capital to develop as a result of its companions fund product growth and commercialization bills. We beforehand owned BioSpecifics and Emisphere, additionally pharmaceutical royalty corporations. They have been each acquired throughout our possession producing engaging returns for our traders.
Vereshchagin Dmitry/Shutterstock.com
Ligand Prescription drugs Included (NASDAQ:LGND) is just not on our checklist of 30 Most Well-liked Shares Amongst Hedge Funds. In accordance with our database, 9 hedge fund portfolios held Ligand Prescription drugs Included (NASDAQ:LGND) on the finish of the second quarter, in comparison with 11 within the earlier quarter. Within the third quarter of 2025, Ligand Prescription drugs Included (NASDAQ:LGND) reported complete income and different revenue, on a GAAP foundation, of $115.5 million, in comparison with $51.8 million in Q3 2024. Whereas we acknowledge the potential of Ligand Prescription drugs Included (NASDAQ:LGND) as an funding, we consider sure AI shares supply better upside potential and carry much less draw back threat. If you happen to’re on the lookout for an especially undervalued AI inventory that additionally stands to learn considerably from Trump-era tariffs and the onshoring development, see our free report on the greatest short-term AI inventory.
[ad_2]
